Mar 28, 2020
Amgen Announces Positive Results At ACC.20/WCC From Phase 3B Study Of Repatha® (Evolocumab) In People Living With HIV Who Have High LDL-Cholesterol
Dec 09, 2019
Beyond Cholesterol: Landmark deCODE Study Elucidates Role of Lipoprotein(a) as Major Risk Factor for Heart Disease
Nov 15, 2019
Amgen And The Duke Clinical Research Institute Announce Initiation Of First Large-Scale Registry To Evaluate Real-World Lipid Management And The Effectiveness Of PCSK9 Inhibitors
Nov 11, 2019
Amgen Highlights Data To Be Presented At AHA 2019 Across Cardiovascular Portfolio
Oct 24, 2019
Amgen To Make Repatha® (evolocumab) Available Exclusively At Its Lower List Price Option In 2020
Aug 28, 2019
U.S. District Court Invalidates Amgen Patent Claims Targeting PCSK9
Aug 28, 2019
New Amgen Data To Be Presented At ESC Congress 2019 Highlight Additional Evidence For Repatha® (Evolocumab) Effectiveness In Cardiovascular Disease Across Multiple Patient Groups
Apr 11, 2019
FH Foundation Expands FIND FH® to Speed Diagnosis of Individuals with Homozygous Familial Hypercholesterolemia
Mar 20, 2019
Innovent Announces First Patient Dosed in a Phase IIa Clinical Study of IBI306, an Anti-PCSK9 Monoclonal Antibody
Mar 15, 2019
Praluent® (alirocumab) now approved in European Union to reduce the risk of cardiovascular events in patients with established cardiovascular disease
Mar 15, 2019
Amgen Announces New Four-Year Outcomes Study To Examine Long-Term Effects Of Repatha® (evolocumab) In High-Risk Cardiovascular Disease (CVD) Patients Without Prior Heart Attack Or Stroke
Mar 06, 2019
New Data From Amgen To Be Presented At ACC.19 Continues To Build Evidence For Repatha® (evolocumab) Across Multiple Patient Populations
Feb 25, 2019
Jury Upholds Amgen's Patents On Repatha® (evolocumab)
Feb 11, 2019
Sanofi and Regeneron offer Praluent® (alirocumab) at a new reduced U.S. list price
Feb 04, 2019
CHMP Recommends Approval of Praluent® (alirocumab) Injection to Reduce Cardiovascular Risk in People with Established Atherosclerotic Cardiovascular Disease
Jan 24, 2019
Amgen Receives NMPA Approval For Repatha® (evolocumab) In China To Reduce The Risk Of Cardiovascular Events
Nov 12, 2018
Amgen Presents Results Highlighting The Long-Term Safety And Efficacy Of Repatha® (Evolocumab) In The Longest Duration Study Of A PCSK9 Inhibitor To Date At AHA Scientific Sessions 2018
Nov 05, 2018
Amgen Announces Presentation Of Research Reinforcing The Long-Term Safety And Efficacy Of Repatha® (Evolocumab) In High-Risk Patients At AHA Scientific Sessions 2018
Oct 26, 2018
Amgen Announces New FOURIER Analysis Showing Benefit With Repatha® (Evolocumab) In High-Risk Patients With Established Cardiovascular Disease And Chronic Kidney Disease
Oct 24, 2018
Amgen Makes Repatha® (Evolocumab) Available In The US At A 60 Percent Reduced List Price